Ads
related to: sellas life sciences stock forecast news- Capital Ideas Webinars
Our Brightest Minds Answer
Your Questions.
- Capital Ideas Podcast
Bringing You the Best Thinking
From Capital Group. Listen Now.
- Markets & Economy
View Our Latest Market Insights
and Get Economic Forecasts.
- Subscribe to Newsletter
Receive Our Latest Investment
Thinking In Your Inbox Each Week.
- Capital Ideas Webinars
Search results
Results From The WOW.Com Content Network
SELLAS Life Sciences Group ( NASDAQ:SLS ) Third Quarter 2022 Results Key Financial Results Net loss: US$7.02m (flat on... SELLAS Life Sciences Group Third Quarter 2022 Earnings: US$0.34 loss per ...
Merger with Sellas Life Sciences. In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced topline data from its Phase 1/2 trial of galinpepimut-S (GPS) in WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian ...
For premium support please call: 800-290-4726 more ways to reach us
List of largest biomedical companies by market capitalization. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) with current market capitalization of at least US$10 billion, ranked by their market capitalization. It does not include biotechnology companies that ...
Calico, short for the California Life Company, [5] [6] was announced on September 18, 2013, prior to Google's restructuring and was founded by former GV CEO Bill Maris. [1] [7] In Google's 2013 Founders Letter, Larry Page described Calico as a company focused on "health, well-being, and longevity ." [8] It was incorporated into Alphabet with ...
Carvana stock ( CVNA) soared more than 30% as the company reported a surprise profit for the prior quarter. The company reported quarterly adjusted earnings per share of $0.23 versus expectations ...
Liminal BioSciences' aim to develop best or first-in-class therapies targeting indications with significant unmet needs, where a novel small molecule approach may be better suited using its drug discovery platform, specialized know-how and data-driven development plans. Liminal BioSciences is a development stage biopharmaceutical company ...
Ads
related to: sellas life sciences stock forecast news